Your session is about to expire
← Back to Search
Procedure
Surgical Approaches for Prostate Cancer (PARTIAL Trial)
N/A
Recruiting
Led By Jim C Hu, MD MPH
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Scheduled for radical prostatectomy for clinically localized prostate cancer
Male sex
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 month, 6 months, 12 months, and 24 months post-surgery
Awards & highlights
PARTIAL Trial Summary
This trial will compare two types of prostate cancer surgery to see which is better at controlling cancer and improving quality of life.
Who is the study for?
This trial is for men aged 40-80 who are scheduled for prostate cancer surgery, can understand English or Spanish, and agree to follow the study rules. It's not for those with advanced lymph node involvement or a history of major pelvic surgery/radiotherapy.Check my eligibility
What is being tested?
The study compares two types of prostate cancer surgeries: standard robot-assisted radical prostatectomy (RP) and a nerve-sparing version called PFS-RP. The goal is to see if PFS-RP offers better urinary function and sexual health without compromising cancer control.See study design
What are the potential side effects?
Potential side effects from both surgeries may include changes in urinary function, sexual health issues like erectile dysfunction, penile shortening/deformity, and possibly an increased risk of developing inguinal hernia.
PARTIAL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for surgery to remove my prostate due to cancer.
Select...
I am male.
Select...
I am between 40 and 80 years old.
PARTIAL Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 1 month, 6 months, 12 months, and 24 months post-surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 month, 6 months, 12 months, and 24 months post-surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Biochemical Recurrence as assessed by Prostate Specific Antigen (PSA)
Surgical Margin Status as assessed by surgical pathology results
Secondary outcome measures
Change in Patient-Reported Penile Shortening and Sexual Function, as measured by a 5-item questionnaire
Change in Urinary and Sexual Function, as measured by the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP)
Change in patient-Reported Penile Curvature/Deformity (Peyronie's Disease), as measured by a 3-item questionnaire
+2 morePARTIAL Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)Experimental Treatment1 Intervention
A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate. These structures are disrupted and removed during conventional radical prostatectomy.
Group II: Robot-assisted radical prostatectomy (RP)Active Control1 Intervention
The conventional robotic-assisted radical prostatectomy is the gold standard approach to prostate cancer surgery.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for prostate cancer include surgical techniques like radical prostatectomy, radiation therapy, and androgen deprivation therapy (ADT). Radical prostatectomy, including the pelvic fascia-sparing approach, involves the surgical removal of the prostate gland and aims to achieve cancer control while preserving urinary and sexual function by sparing surrounding tissues.
This matters for patients as it can potentially reduce complications such as urinary incontinence and erectile dysfunction. Radiation therapy uses high-energy rays to target and kill cancer cells, while ADT reduces testosterone levels to slow the growth of cancer.
Each treatment has distinct mechanisms and side effects, and the choice depends on the cancer's stage and the patient's overall health and preferences.
Prostate Leiomyosarcoma: A Rare Misleading Tumor.Extraperitoneal laparo-endoscopic single-site radical prostatectomy: first experience.Critical appraisal of outcomes following open radical prostatectomy.
Prostate Leiomyosarcoma: A Rare Misleading Tumor.Extraperitoneal laparo-endoscopic single-site radical prostatectomy: first experience.Critical appraisal of outcomes following open radical prostatectomy.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,059 Previous Clinical Trials
1,315,543 Total Patients Enrolled
48 Trials studying Prostate Cancer
34,011 Patients Enrolled for Prostate Cancer
National Institutes of Health (NIH)NIH
2,720 Previous Clinical Trials
7,493,627 Total Patients Enrolled
28 Trials studying Prostate Cancer
6,357 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,952,764 Total Patients Enrolled
564 Trials studying Prostate Cancer
528,464 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am scheduled for surgery to remove my prostate due to cancer.I have had major surgery or radiation treatment in my pelvic area.I can read and speak English or Spanish.I am male.I am between 40 and 80 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)
- Group 2: Robot-assisted radical prostatectomy (RP)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger